Product image of Jamesi Novum (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Jamesi Novum

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Jamesi Novum (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jamesi Novum, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels when used as part of a comprehensive treatment plan that includes diet and exercise.

GNH India supplies Jamesi Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Jamesi Novum is used in the treatment of disorders related to impaired glucose regulation, primarily type 2 diabetes mellitus.
  • Type 2 diabetes mellitus: improves fasting and post‑prandial glucose levels.
  • Adjunct to diet and exercise: enhances overall glycaemic control when metformin alone is insufficient.
  • Combination therapy with other antidiabetics: provides additional HbA1c reduction in patients requiring multi‑drug regimens.

How It Works

  • Metformin decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, while Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased levels of endogenous incretin hormones (GLP‑1 and GIP). The elevated incretins enhance glucose‑dependent insulin secretion and suppress glucagon release, together producing a complementary reduction in blood glucose.

Side Effects

Jamesi Novum may cause adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhoea: loose stools, often transient.
  • Abdominal discomfort: cramping or pain.
  • Metallic taste: altered taste sensation.
  • Headache: mild to moderate.
  • Decreased appetite: reduced food intake.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: inflammation of the pancreas.
  • Severe skin reactions: such as Stevens‑Johnson syndrome.
  • Hepatic dysfunction: abnormal liver enzymes.
  • Renal impairment: worsening kidney function.

Precautions & Warnings

  • Before prescribing Jamesi Novum, clinicians should consider several safety factors.
  • Renal function assessment: evaluate eGFR and avoid use in severe renal impairment.
  • Hepatic function monitoring: check liver enzymes periodically.
  • Risk of lactic acidosis: contraindicated in patients with conditions predisposing to hypoxia.
  • Hypoglycaemia monitoring: especially when used with insulin or sulfonylureas.
  • Cardiac failure caution: avoid in uncontrolled heart failure.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Jamesi Novum can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Concomitant use with iodinated contrast agents: may precipitate renal dysfunction.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): increase Sitagliptin exposure.
  • Co‑administration with other agents that increase lactic acidosis risk (e.g., alcohol excess).

Moderate Interactions (Monitor Closely)

  • Diuretics (e.g., furosemide): may affect renal clearance of Metformin.
  • ACE inhibitors or ARBs: monitor renal function and potassium levels.
  • Beta‑blockers: may mask hypoglycaemia symptoms; observe blood glucose closely.

Frequently Asked Questions

Jamesi Novum is prescribed for adults with type 2 diabetes mellitus to improve glycaemic control. It combines metformin, which reduces hepatic glucose production, with sitagliptin, which enhances insulin secretion in response to meals, providing a complementary approach to lower blood glucose levels.

Metformin Hydrochloride lowers blood glucose primarily by inhibiting hepatic gluconeogenesis, thereby reducing the amount of glucose released into the bloodstream. It also increases peripheral insulin sensitivity, facilitating glucose uptake by muscle and fat tissues, which together help to lower fasting plasma glucose.

The dosage of Jamesi Novum is individualized by the prescribing clinician based on the patient’s renal function, glycaemic targets, and concomitant therapies. The prescriber determines the appropriate strength and dosing schedule, which may be adjusted over time according to therapeutic response and safety monitoring.

Safety of Jamesi Novum in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Jamesi Novum, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jamesi Novum combines a biguanide (metformin) with a DPP‑4 inhibitor (sitagliptin), offering both reduced hepatic glucose output and enhanced incretin‑mediated insulin secretion. Compared with metformin alone, it provides greater HbA1c reduction, while avoiding the injectable route required for GLP‑1 analogues.

Jamesi Novum should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Jamesi Novum is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal metabolic complication, and severe hypoglycaemia when used with other glucose‑lowering agents. Patients should be monitored for signs of abdominal pain, rapid breathing, or unexplained fatigue, and should seek immediate medical attention if these occur.

Jamesi Novum is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, acute or chronic metabolic acidosis, and in those with uncontrolled heart failure. It should also be avoided in individuals with a history of lactic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT